Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Added to Carboplatin-based Neoadjuvant Chemotherapy in Early Triple Negative Breast Cancer
2022-501102-35-00Phase 3Authorised
- Sponsor
- Region Skåne
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of capecitabine in triple-negative breast cancer (TNBC) (2 arms), sponsored by Region Skåne. Primary endpoint: Pathologic complete response (pCR). Planned start Jun 2024; status: authorised.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-501102-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501102-35-00.